Dalli gets nod as new EU health commissioner, but process not over yet
This article was originally published in RAJ Devices
John Dalli is a step closer to becoming the next head of health and consumer policy at the European Commission following the news that his confirmation hearing before the European Parliament has been given a positive assessment.
You may also be interested in...
EU marketing applications from Vertex and Roche have reverted to standard review timelines at the European Medicines Agency. The outcomes of three fast-track requests that companies have made for their planned filings are still unknown.
Vertex is hoping for EU approval in Q4 of its cystic fibrosis triple combination therapy, Trikafta. It wants the same licence in the EU as it has in the US, where the product has already become a best seller for the company.
KTE-X19, Kite’s potential new CAR-T therapy, will in the end be fast-tracked at the European Medicines Agency. Lilly failed to secure the speedy review it was seeking for selpercatinib